SAVA vs. COLL, VRCA, NATR, SCPH, VSTM, ALKS, PRGO, CRNX, AXSM, and BHVN
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Collegium Pharmaceutical (COLL), Verrica Pharmaceuticals (VRCA), Nature's Sunshine Products (NATR), scPharmaceuticals (SCPH), Verastem (VSTM), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), and Biohaven (BHVN). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership.
Cassava Sciences presently has a consensus target price of $131.00, suggesting a potential upside of 483.52%. Collegium Pharmaceutical has a consensus target price of $39.00, suggesting a potential upside of 20.26%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cassava Sciences is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Cassava Sciences has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.
Collegium Pharmaceutical received 281 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.43% of users gave Cassava Sciences an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.
38.1% of Cassava Sciences shares are held by institutional investors. 9.0% of Cassava Sciences shares are held by company insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Collegium Pharmaceutical has a net margin of 16.46% compared to Cassava Sciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.98% beat Cassava Sciences' return on equity.
In the previous week, Collegium Pharmaceutical had 10 more articles in the media than Cassava Sciences. MarketBeat recorded 13 mentions for Collegium Pharmaceutical and 3 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.72 beat Collegium Pharmaceutical's score of 0.69 indicating that Cassava Sciences is being referred to more favorably in the media.
Summary
Collegium Pharmaceutical beats Cassava Sciences on 10 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
